TIGENIX (D) : TiGenix signs up 4th major hospital in the Netherlands for ChondroCelect and obtains national reimbursement retroactive per January 1, 2011
07/17/2012| 03:53am US/Eastern
Recommend:
"Our close collaboration with the Dutch hospitals is key to
making ChondroCelect available to patients in the
Netherlands," said Eduardo Bravo, CEO of TiGenix. "Dutch
scientists and clinicians have made important contributions
to the development of this innovative cartilage repair
therapy. Patients who suffer from cartilage lesions in the
knee that cause recurrent pain and can be incapacitating can
now be routinely treated and literally find their footing
again. We expect to soon expand the number of hospitals in
the Netherlands where ChondroCelect is available."
Damage to the articular cartilage in the knee can be caused
by sports or professional activities in which the knee is
repeatedly and forcefully impacted. It is a condition that
predominantly occurs in young adults, who as a result suffer
from recurrent pain, locking or limited range of motion, and
risk being incapacitated. TiGenix has developed ChondroCelect
as a therapy to help patients regain their mobility and fully
active lives by effectively repairing the damaged cartilage
in the knee.
For more information:
Eduardo Bravo Claudia D'Augusta Chief Executive Officer Chief
Financial Officer eduardo.bravo@tigenix.com
claudia.daugusta@tigenix.com
Hans Herklots
Director Investor & Media Relations hans.herklots@tigenix.com
+32 16 39 60 97
1
About ChondroCelect®
ChondroCelect® for cartilage regeneration in the knee is an
implantation suspension of characterized viable autologous
(from the patient her- or himself) cartilage cells. The
product is administered to patients in an autologous
chondrocyte implantation procedure known as Characterized
Chondrocyte Implantation (CCI), a surgical procedure to treat
cartilage defects, in conjunction with debridement
(preparation of the defect bed), a physical seal of the
lesion (placement of a biological membrane, preferentially a
collagen membrane) and rehabilitation.
Cartilage defects of the knee are very common and the
spontaneous healing capacity of cartilage is limited.
Currently, roughly 2 million cases of articular cartilage
defects of the knee are diagnosed worldwide every year.
TiGenix estimates that in Europe and the United States around
130,000 patients are eligible for treatment with cartilage
regeneration products such as ChondroCelect.
ChondroCelect is the first cell-based product to successfully
complete the entire development track from research to
clinical development, and was approved by the European
Medicines Agency as an Advanced Medicinal Therapy Product in
October 2009. ChondroCelect is to date the only EMA approved
cartilage repair therapy, and is commercially available in
Belgium, the Netherlands, Luxemburg, Germany, the United
Kingdom, Finland, and Spain.
About TiGenix
TiGenix NV (NYSE Euronext Brussels: TIG) is a leading
European cell therapy company with a marketed cell therapy
product for cartilage repair, ChondroCelect®, and a strong
pipeline with clinical stage allogeneic adult stem cell
programs for the treatment of autoimmune and inflammatory
diseases. TiGenix is based out of Leuven (Belgium) and has
operations in Madrid (Spain), and Sittard-Geleen (the
Netherlands). For more information please visit www.tigenix.com.
Forward-looking information
This document may contain forward-looking statements and
estimates with respect to the anticipated future performance
of TiGenix and the market in which it operates. Certain of
these statements, forecasts and estimates can be recognized
by the use of words such as, without limitation, "believes",
"anticipates", "expects", "intends", "plans", "seeks",
"estimates", "may", "will" and "continue" and similar
expressions. They include all matters that are not historical
facts. Such statements, forecasts and estimates are based on
various assumptions and assessments of known and unknown
risks, uncertainties and other factors, which were deemed
reasonable when made but may or may not prove to be correct.
Actual events are difficult to predict and may depend upon
factors that are beyond TiGenix' control. Therefore, actual
results, the financial condition, performance or achievements
of TiGenix, or industry results, may turn out to be
materially different from any future results, performance or
achievements expressed or implied by such statements,
forecasts and estimates. Given these uncertainties, no
representations are made as to the accuracy or fairness of
such forward-looking statements, forecasts and estimates.
Furthermore, forward-looking statements, forecasts and
estimates only speak as of the date of the publication of
this document. TiGenix disclaims any obligation to update any
such forward-looking statement, forecast or estimates to
reflect any change in TiGenix' expectations with regard
thereto, or any change in events, conditions or circumstances
on which any such statement, forecast or estimate is based,
except to the extent required by Belgian law.
2
distributed by
|
|
Recommend :
